EYPT
HealthcareEyePoint Pharmaceuticals, Inc. · Biotechnology · $1B
What is EyePoint Pharmaceuticals, Inc.?
EyePoint Pharmaceuticals focuses on developing and commercializing sustained-release drug delivery products for serious eye diseases. Headquartered in Watertown, the company targets conditions ranging from diabetic macular edema to chronic uveitis.
EyePoint generates revenue by commercializing ophthalmic micro-inserts and implants that deliver medication directly inside the eye over extended periods. Its approved products address diabetic macular edema, chronic non-infectious uveitis, and post-surgical inflammation. The company also advances a clinical-stage pipeline targeting wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Strategic collaborations with partners including Alimera Sciences and Bausch & Lomb support both commercial reach and development efforts.
EyePoint Pharmaceuticals was incorporated in 1987 and is headquartered in Watertown, US.
- ILUVIEN — sustained-release micro-insert for diabetic macular edema
- YUTIQ — intravitreal implant for chronic non-infectious uveitis
- DEXYCU — intraocular suspension for post-operative ocular inflammation
- EYP-1901 — investigational twice-yearly retinal disease treatment
- YUTIQ50 — next-generation uveitis implant in development
Is EYPT a Good Stock to Buy?
UQS Score rates EYPT as Poor overall, placing it in the lowest tier of our composite ranking system.
Among the five pillars, Risk stands out as the relative bright spot, suggesting the company carries a more manageable risk profile than its Poor overall score might imply. This may reflect the company's focused therapeutic niche and existing commercial partnerships.
Quality, Moat, and Growth all register as Weak, pointing to meaningful challenges in business durability, competitive positioning, and near-term expansion. Valuation is rated Elevated, meaning the current price does not appear to offer a margin of safety relative to fundamentals.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does EYPT pay dividends?
No — EyePoint Pharmaceuticals, Inc. does not currently pay a dividend.
EYPT does not currently pay a dividend. For a clinical-stage and early-commercial pharmaceutical company, this is typical — available capital is directed toward research, clinical trials, and pipeline advancement rather than shareholder distributions. Investors in EYPT are generally seeking potential appreciation from pipeline progress rather than income.
When does EYPT report earnings?
EyePoint Pharmaceuticals reports earnings on a quarterly cadence, consistent with US-listed public companies.
Given the Weak ratings across Quality and Growth pillars, recent reporting periods reflect the pressures common to small-cap specialty pharma companies balancing commercial-stage products against ongoing pipeline investment. Revenue visibility remains tied to product adoption and partnership milestones.
For the most recent quarter's results and guidance, visit EyePoint Pharmaceuticals' investor relations page directly.
EYPT Price History
+43.5% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in EyePoint Pharmaceuticals, Inc.?
Based on EyePoint Pharmaceuticals, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
EYPT Long-term Outlook
The Growth pillar rating of Weak signals that near-term expansion is not yet a defining strength for EyePoint. The pipeline candidate EYP-1901, targeting large retinal disease indications, represents the most significant potential catalyst, but clinical-stage assets carry inherent uncertainty. The Elevated Valuation rating suggests the market may already be pricing in optimistic pipeline outcomes, which could limit upside if trial results disappoint. The Good Risk rating provides some reassurance that the company is not in acute financial distress.
Growth drivers
- EYP-1901 clinical advancement in wet AMD and diabetic retinopathy
- Expanded commercial partnerships with Alimera Sciences and Bausch & Lomb
- Growing addressable market for sustained-release ophthalmic drug delivery
Key risks
- Clinical trial failure or delays for pipeline candidates
- Elevated valuation leaving limited room for execution shortfalls
- Competitive pressure from larger ophthalmic and biotech players
EYPT vs Peers
EyePoint operates in a competitive specialty biotech landscape alongside companies pursuing distinct therapeutic and platform strategies.
Viridian focuses on thyroid eye disease and related antibody therapies, a different ophthalmic indication from EyePoint's retinal and uveitis focus.
Iovance pursues tumor-infiltrating lymphocyte cell therapies for oncology, representing a fundamentally different modality and disease area than EyePoint's sustained-release ocular implants.
AbCellera operates as an antibody discovery platform business, partnering broadly across therapeutic areas rather than concentrating on ophthalmic drug delivery.
Frequently Asked Questions
What does EyePoint Pharmaceuticals do?
EyePoint Pharmaceuticals develops and commercializes sustained-release drug delivery products for serious eye diseases. Its approved products treat diabetic macular edema, chronic non-infectious uveitis, and post-surgical ocular inflammation. The company also has a clinical pipeline targeting wet age-related macular degeneration and diabetic retinopathy, supported by partnerships with established ophthalmic companies.
Does EYPT pay dividends?
EYPT does not pay a dividend. As a small-cap specialty pharmaceutical company with active clinical programs, EyePoint directs its capital toward research, development, and commercialization activities rather than shareholder distributions. Investors should not expect income from this holding.
When does EYPT report earnings?
EyePoint Pharmaceuticals reports financial results on a quarterly basis, in line with standard US public company requirements. For precise dates of upcoming earnings releases, check the investor relations section of EyePoint's official website, as our data source does not provide specific forward-looking earnings dates.
Is EYPT a good stock to buy?
The UQS Score rates EYPT as Poor, reflecting Weak readings across Quality, Moat, and Growth pillars alongside an Elevated Valuation. The Good Risk rating is a relative positive. Whether EYPT fits a portfolio depends on individual risk tolerance and conviction in the company's pipeline. The full pillar breakdown is available to UQS Pro members.
Is EYPT overvalued?
The UQS Valuation pillar for EYPT is rated Elevated, suggesting the current market price may not offer a meaningful margin of safety relative to the company's fundamental profile. This is not uncommon for clinical-stage pharma companies where the market prices in future pipeline success, but it does increase downside risk if milestones are missed.
How does EYPT compare to its competitors?
EYPT operates in a distinct niche — sustained-release ophthalmic implants — that differs from peers like Viridian Therapeutics, Iovance Biotherapeutics, and AbCellera Biologics, which pursue antibody therapies, cell therapies, and platform-based discovery respectively. EyePoint's focus is narrower and more specialized. Side-by-side UQS pillar comparisons are available on each company's profile page.
What is EYPT's market cap bracket?
EYPT is classified as a small-cap stock. Small-cap companies typically carry higher volatility and liquidity risk than large- or mega-cap peers, and they often depend more heavily on the success of a limited number of products or pipeline assets — both of which apply to EyePoint's current situation.
Who founded EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals traces its origins to pSivida Corp., which was incorporated in 1987. The company rebranded to EyePoint Pharmaceuticals in March 2018 to better reflect its ophthalmic focus. Detailed founding history is publicly available through the company's official filings and investor relations materials.
Is EYPT a long-term quality investment?
As a long-term quality indicator, the UQS Score rates EYPT as Poor. Weak readings in Quality, Moat, and Growth suggest the company has not yet demonstrated the durable business characteristics typically associated with long-term compounders. Pipeline success — particularly for EYP-1901 — would be necessary to meaningfully improve this profile over time.
What is the main competitive advantage of EyePoint Pharmaceuticals?
EyePoint's primary differentiation lies in its proprietary sustained-release drug delivery technology, which enables medications to be administered infrequently inside the eye over months. This platform underpins both its approved products and its pipeline. However, the UQS Moat pillar rates this advantage as Weak, indicating the competitive position is not yet considered durable at the current stage.
What sector does EYPT belong to?
EYPT belongs to the Healthcare sector, specifically within specialty pharmaceuticals focused on ophthalmology. The company sits at the intersection of drug delivery technology and eye disease treatment, competing in a space that includes both large ophthalmic divisions of major pharma companies and smaller biotech peers.
Is EYPT a growth stock or value stock?
Based on UQS pillar labels, EYPT does not fit neatly into either category. The Growth pillar is rated Weak, meaning near-term expansion is not a current strength. The Valuation pillar is rated Elevated, ruling out a traditional value characterization. EYPT is better described as a clinical-stage pipeline bet than a conventional growth or value holding.
Unlock Full EYPT Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access detailed financial metrics and trend data
- ✓Compare EYPT against sector peers side by side
- ✓Screen for higher-quality small-cap healthcare alternatives
- ✓Track pillar changes as new earnings data arrives
- ✓Get the full analyst-grade view in one dashboard
Pro Analysis
EYPT — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 26.1 | 3.3 | 26.0 | 39.1 | 73.3 | 0.0 | +0.1 |
| Apr 2, 2026 | 26.0 | 3.3 | 26.0 | 39.1 | 72.1 | 0.0 | — |
EYPT — Pillar Breakdown
Quality
— 3.3/100 (25%)EyePoint Pharmaceuticals, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 39.1/100 (20%)EyePoint Pharmaceuticals, Inc. shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 73.3/100 (15%)EyePoint Pharmaceuticals, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)EyePoint Pharmaceuticals, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 26/100 (25%)EyePoint Pharmaceuticals, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for EYPT.
Score Composition
Financial Data
More Stock Analysis
How is the EYPT UQS Score Calculated?
The UQS (Unified Quality Score) for EyePoint Pharmaceuticals, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses EyePoint Pharmaceuticals, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether EyePoint Pharmaceuticals, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.